Pipeline | Decibel Therapeutics

Small Molecules:

PROGRAM

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

DB-020 Cisplatin Ototoxicity

PROGRAM

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

DB-020 Cisplatin Ototoxicity

DB-041 Aminoglycoside Ototoxicity

PROGRAM

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

DB-041 Aminoglycoside Ototoxicity

Mechanism: It is thought that aminoglycosides enter cochlear and vestibular hair cells through a specialized mechano-electrical transducer (MET). The pore of the MET channel is large enough to permit the entry of aminoglycosides into the compartment where toxicity occurs. DB-041 is believed to protect against aminoglycoside-induced hair cell death by blocking the entry of aminoglycoside molecules through the MET channel.

Unmet need: Aminoglycoside antibiotics are often the only effective option to treat severe infections despite labeled warnings regarding risk of permanent hearing loss and balance problems. Particularly susceptible populations include those treated for pulmonary exacerbations associated with cystic fibrosis, non-tuberculous mycobacterial infections, and multidrug-resistant tuberculosis.

Gene Therapeutics:

PROGRAM

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

DB-XX1* Balance Dysfunction

PROGRAM

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

DB-XX1* Balance Dysfunction

DB-XX2* Monogenic Hearing Loss: Gene 1

PROGRAM

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

DB-XX2* Monogenic Hearing Loss: Gene 1

DB-XX3* Monogenic Hearing Loss: Gene 2

PROGRAM

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

DB-XX3* Monogenic Hearing Loss: Gene 2

DB-XX4* Monogenic Hearing Loss: Gene 3

PROGRAM

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

DB-XX4* Monogenic Hearing Loss: Gene 3

Biologics:

PROGRAM

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

DB-XX5* Tinnitus; Auditory Neuropathy

PROGRAM

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

DB-XX5* Tinnitus; Auditory Neuropathy

Undisclosed:

PROGRAM

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

Novel target ID Noise, Age, Tinnitus, Balance

PROGRAM

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

Novel target ID Noise, Age, Tinnitus, Balance

PROGRAM

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

DB-020 Cisplatin Ototoxicity

PROGRAM

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

DB-020 Cisplatin Ototoxicity

Small Molecule

DB-041 Aminoglycoside Ototoxicity

PROGRAM

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

DB-041 Aminoglycoside Ototoxicity

Small Molecule

DB-XX1* Balance Dysfunction

PROGRAM

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

DB-XX1* Balance Dysfunction

Gene Therapy

DB-XX2* Monogenic Hearing Loss: Gene 1

PROGRAM

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

DB-XX2* Monogenic Hearing Loss: Gene 1

Gene Therapy

DB-XX3* Monogenic Hearing Loss: Gene 2

PROGRAM

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

DB-XX3* Monogenic Hearing Loss: Gene 2

Gene Therapy

DB-XX4* Monogenic Hearing Loss: Gene 3

PROGRAM

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

DB-XX4* Monogenic Hearing Loss: Gene 3

Gene Therapy

DB-XX5* Tinnitus; Auditory Neuropathy

PROGRAM

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

DB-XX5* Tinnitus; Auditory Neuropathy

Biologic

Novel target ID Noise, Age, Tinnitus, Balance

PROGRAM

TARGET ID & VALIDATION

DRUG DISCOVERY

IND ENABLING STUDIES (GLP)

PHASE I

Novel target ID Noise, Age, Tinnitus, Balance

Undisclosed

^{* Currently included in the Decibel Regeneron collaboration. Decibel retains worldwide development and commercial rights. Regeneron co-funds the development of collaboration programs and receives tiered royalties based on net sales.}

Learn about our approach